Pros | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Among most bought funds within the category. | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | ![]() 5Y returns in the bottom 25% of the category. |
INDMoney rank | 3/8 | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 7 Years | 12 Years | ||
Fund Size | 6162 Cr | 8357 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 1.04% | 0.89% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 40 | 41 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.71%) Dr Reddy's Laboratories Ltd (9.47%) Divi's Laboratories Ltd (9.23%) Cipla Ltd (7.39%) Aurobindo Pharma Ltd (6.53%) | Sun Pharmaceuticals Industries Ltd (11.94%) Divi's Laboratories Ltd (7.34%) Cipla Ltd (6.09%) Lupin Ltd (6.09%) Apollo Hospitals Enterprise Ltd (5.91%) | ||
No of Sectors | 3 | 1 | ||
Top 3 Sectors | Health (97.35%) Basic Materials (1.5%) Financial Services (1.15%) | Health (100%) | ||
Equity % | 95.88% | 99.48% | ||
Debt % | - | - | ||
P/E | 31.02 | 36.11 | ||
P/B | 4.22 | 5.78 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 0.9% | -0.19% | ||
3-Month Return | 3.1% | 0.64% | ||
6-Month Return | 17.43% | 12.17% | ||
1-Year Return | 4.55% | -0.52% | ||
3-Year Return | 30.56% | 25% | ||
5-Year Return | 21.73% | 19.15% |
Sharpe | 1.31 | 1.06 | ||
Alpha | 4.41 | 0.66 | ||
Beta | 0.94 | 0.91 | ||
Standard Deviation | 15.52 | 15.05 | ||
Information Ratio | 1.42 | -0.24 |
Description | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Dharmesh Kakkad,Sharmila D’mello | Sailesh Raj Bhan,Kinjal Desai |